377
Views
17
CrossRef citations to date
0
Altmetric
Liver and Biliary Tract

Hepatic expression and serum levels of syndecan 1 (CD138) in patients with nonalcoholic fatty liver disease

, , , , &
Pages 1488-1493 | Received 07 Aug 2012, Accepted 22 Aug 2012, Published online: 08 Nov 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Yusuf Yilmaz, Atakan Yesil, Fatma Gerin, Rabia Ergelen, Hakan Akin, Çigdem Ataizi Celikel & Nese Imeryuz. (2014) Detection of hepatic steatosis using the controlled attenuation parameter: a comparative study with liver biopsy. Scandinavian Journal of Gastroenterology 49:5, pages 611-616.
Read now

Articles from other publishers (16)

Arya Mariam Roy, Renuka Iyer & Sayan Chakraborty. (2023) The extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability. Cell Reports Medicine 4:9, pages 101170.
Crossref
Nihat YUMUŞAK. (2023) Immunohistochemical Alterations of Syndecan-1 in Sheep Liver with Cystic EchinococcosisKistik Ekinokokkozlu Koyun Karaciğerlerinde Sindekan-1’in İmmünohistokimyasal Değişiklikleri. Harran Üniversitesi Veteriner Fakültesi Dergisi.
Crossref
Helen Huang, Wireko A. Awuah, Tulika Garg, Jyi Cheng Ng, Aashna Mehta, Krishna Ramamoorthy, Jacob Kalmanovich & Mohammad M. Hasan. (2023) Prospects of evolution-based artificial intelligence models in genome-wide studies to stratify genetic risk variants in nonalcoholic fatty liver disease. Annals of Medicine & Surgery 85:6, pages 2743-2748.
Crossref
Dixa Sharma & Palash Mandal. (2022) NAFLD: genetics and its clinical implications. Clinics and Research in Hepatology and Gastroenterology 46:9, pages 102003.
Crossref
Andrea Reszegi, Péter Tátrai, Eszter Regős, Ilona Kovalszky & Kornélia Baghy. (2022) Syndecan-1 in liver pathophysiology. American Journal of Physiology-Cell Physiology 323:2, pages C289-C294.
Crossref
Francesco Dituri, Gianluigi Gigante, Rosanna Scialpi, Serena Mancarella, Isabel Fabregat & Gianluigi Giannelli. (2022) Proteoglycans in Cancer: Friends or Enemies? A Special Focus on Hepatocellular Carcinoma. Cancers 14:8, pages 1902.
Crossref
Shu Jing Xia, Li Zhong Tang, Wen Hua Li, Zhao Shan Xu, Li Li Zhang, Feng Gan Cheng, Hong Xia Chen, Zi Hua Wang, Yu Cheng Luo, An Na Dai & Jian Gao Fan. (2021) Serum syndecan‐4 is associated with nonalcoholic fatty liver disease. Journal of Digestive Diseases 22:9, pages 536-544.
Crossref
Eszter Regős, Katalin Karászi, Andrea Reszegi, András Kiss, Zsuzsa Schaff, Kornélia Baghy & Ilona Kovalszky. (2019) Syndecan-1 in Liver Diseases. Pathology & Oncology Research 26:2, pages 813-819.
Crossref
Bahram Namjou, Todd Lingren, Yongbo Huang, Sreeja Parameswaran, Beth L. Cobb, Ian B. Stanaway, John J. Connolly, Frank D. Mentch, Barbara Benoit, Xinnan Niu, Wei-Qi Wei, Robert J. Carroll, Jennifer A. Pacheco, Isaac T. W. Harley, Senad Divanovic, David S. Carrell, Eric B. Larson, David J. Carey, Shefali Verma, Marylyn D. Ritchie, Ali G. Gharavi, Shawn Murphy, Marc S. Williams, David R. Crosslin, Gail P. Jarvik, Iftikhar J. Kullo, Hakon Hakonarson, Rongling Li, Stavra A. Xanthakos & John B. Harley. (2019) GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network. BMC Medicine 17:1.
Crossref
Burcu Hasturk, Yusuf Yilmaz & Fatih Eren. (2019) Potential clinical variants detected in mitochondrial DNA D-loop hypervariable region I of patients with non-alcoholic steatohepatitis. Hormones 18:4, pages 463-475.
Crossref
Radu-Stefan Miftode, Ionela-Lăcrămioara Şerban, Amalia-Stefana Timpau, Ionela-Larisa Miftode, Adriana Ion, Ana-Maria Buburuz, Alexandru-Dan Costache & Irina-Iuliana Costache. (2019) Syndecan-1: A Review on Its Role in Heart Failure and Chronic Liver Disease Patients’ Assessment. Cardiology Research and Practice 2019, pages 1-7.
Crossref
Eszter Regős, Hadeer Hesham Abdelfattah, Andrea Reszegi, László Szilák, Klára Werling, Gábor Szabó, András Kiss, Zsuzsa Schaff, Ilona Kovalszky & Kornélia Baghy. (2018) Syndecan-1 inhibits early stages of liver fibrogenesis by interfering with TGFβ1 action and upregulating MMP14. Matrix Biology 68-69, pages 474-489.
Crossref
M. E Statsenko, S. V Turkina, A. A Ermolenko, E. E Gorbacheva & A. V Sabanov. (2018) NON-ALCOHOLIC FATTY LIVER DISEASE -A NEW RISK FACTOR FOR THE DEVELOPMENT OF CHRONIC KIDNEY DISEASE. Journal of Volgograd State Medical University 15:2, pages 125-130.
Crossref
Amirhossein Sahebkar, Elena Sancho, David Abelló, Jordi Camps & Jorge Joven. (2017) Novel circulating biomarkers for non‐alcoholic fatty liver disease: A systematic review. Journal of Cellular Physiology 233:2, pages 849-855.
Crossref
Giovanni Musso, Maurizio Cassader, Solomon Cohney, Franco De Michieli, Silvia Pinach, Francesca Saba & Roberto Gambino. (2016) Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities. Diabetes Care 39:10, pages 1830-1845.
Crossref
Claudia Giambartolomei, Damjan Vukcevic, Eric E. Schadt, Lude Franke, Aroon D. Hingorani, Chris Wallace & Vincent Plagnol. (2014) Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary Statistics. PLoS Genetics 10:5, pages e1004383.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.